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Overweight or obesity, along with type 2 diabetes mellitus, is one of the major causes of 
cardiovascular morbidity and mortality. In the heart, fat is deposited inside – myocardial 
triglyceride content, and outside the myocardium, so called intrathoracic fat which is 
divided by pericardium to epicardial and pericardial adipose tissue. 
The aim of this project was to establish the association between intrathoracic adipose 
tissue distribution and metabolic profile of patients with type 2 diabetes mellitus. 
The study group consisted of 31 patients (78 % male, mean age 62 ± 8, mean BMI 32 
kg/m2) with type 2 diabetes mellitus. Magnetic resonance imaging was used to assess 
cardiac fat volumes. Additional laboratory and anthropometric measurements were 
performed. 
The study showed that men tend to have higher cardiac adipose tissue mass than women 
(epicardial 263 and 234 g, p = .168; pericardial 272 and 176 g, p = .013; intrathoracic 
535	and	410	g,	p	=	.018). Subjects with larger waist circumference (more than 102 cm 
in men, and more than 88 cm in women) showed higher cardiac adipose tissue mass than 
subjects with smaller waist circumference; however, there were no statistically significant 
differences (epicardial 261 and 240 g; pericardial 251 and 243 g). There was a positive 
correlation between cardiac fat mass and waist circumference (epicardial rs = .398, p = 
.027; intrathoracic rs = .378, p = .036). 
Study results showed that cardiac fat mass measurement by MRI might provide important 
information about the metabolic and cardiovascular risk. In the future, it would be 
interesting to investigate the association between cardiac fat depots and the amount of 
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Type 2 diabetes mellitus (T2DM) is a growing public health concern worldwide. Over 
the past few decades, the incidence of diabetes has been steadily increasing in countries 
of all income levels, especially in low- and middle-income countries. Sedentary lifestyle, 
dietary preferences, urbanization, and many other factors account for the increasing risk 
of developing T2DM all over the world (International Diabetes Federation, 2015). 
 
T2DM is a major cause of cardiovascular morbidity and mortality (Martín-Timón et al., 
2014). If diabetes incidence continues to increase as it has been predicted, cardiovascular 
(CV) disease epidemic will become inevitable which will lead to the immense global 
healthcare burden (Chiha et al., 2012). However, CV risk is increased long before a 
patient is diagnosed with diabetes. Metabolic syndrome is a group of risk factors leading 
to CV diseases and diabetes. These factors include abdominal obesity, increased blood 
pressure (BP), increased cholesterol, insulin resistance (IR) and increased fasting plasma 
glucose (FPG) (National Cholesterol Education Program, 2002; Alberti and Zimmet, 
1998; American Diabetes Association, 2016). Overweight or obesity is considered as a 
main risk factor for CV diseases (American Diabetes Association, 2016). 
 
In the heart, fat is deposited inside as triglycerides increasing myocardial triglyceride 
content (MTC). Fat is also located outside the myocardium. This so called intrathoracic 
fat is divided by pericardium to epicardial and pericardial adipose tissue (Honkala et al., 
2017). Cardiac adipose tissue plays an important role in the development of CV diseases 
due to three main reasons: (1) Intrathoracic adipose tissue produces inflammatory 
cytokines, chemokines and hormones which leads to inflammation in coronary vessels 
(Mazurek et al., 2003; Guzzardi and Iozzo, 2011); (2) Increased intrathoracic fat forms a 
mechanical restraint affecting cardiac function (Iacobellis et al., 2005); (3) Increased 
MTC is associated with fatty acid oversupply to the heart, mitochondrial dysfunction	and	
increased oxidative stress (Nyman et al., 2013; Lim and Meigs, 2014; McGavock et al., 
2007). Heart adiposity has been attracting a lot of interest since recent developments in 
the field of noninvasive imaging which allows to quite accurately quantify fat depots.	
 




2 LITERATURE REVIEW 
 
2.1 Heart adiposity 
 
Cardiac adipose tissue includes three distinct fat depots: (1) MTC; (2) epicardial adipose 
tissue; (3) pericardial adipose tissue (Honkala et al., 2017). Myocardial fat is defined as 
the depots of triglyceride within cardiomyocytes. Normally, MTC is regulated by the FFA 
oxidation. Defect in the FFA oxidation increases accumulation of triglycerides in 
cardiomyocytes (Szczepaniak et al., 2003; Kankaanpää et al., 2006). 
 
Adipose tissue surrounding the heart, so called intrathoracic fat, consists of epicardial and 
pericardial fat (Fig.1). Epicardial and pericardial adipose tissue have clearly distinctive 
characteristics – anatomical, physiological, embryological, biomolecular, and clinical 





Figure 2 shows the localization of two fat depots outside the myocardium. Epicardial fat 
refers to the layer of adipose tissue between myocardium and a visceral layer of 
pericardium. It does not extensively cover the heart – its volume depends on location, 
with highest concentration alongside the coronary arteries and in the atrioventricular and 
interventricular grooves. Epicardial fat is not separated from the heart muscle by a fascia 
and it shares the same blood supply from the coronary arteries (Iacobellis, 2009). 
Pericardial fat is located between visceral and parietal pericardium and also surrounds 
pericardium (Iacobellis et al., 2005). It receives blood from non-coronary sources, 
including the pericardiophrenic artery, a branch of the internal mammary artery (Iozzo, 






The origin of two fat depots also differs. Epicardial fat, similar to mesenteric and omental 
fat, emerges from mesothelial cells, and pericardial fat evolves from thoracic 
mesenchyme (Iacobellis et al., 2005). As it was mentioned above, epicardial fat receives 
blood from coronary circulation. On the contrary, pericardial fat is provided with blood 
by the pericardiophrenic artery, a branch of the internal thoracic artery, thus it has non-
coronary sources of blood supply (Bertaso et al., 2013). 
 
In health, cardiac fat depots play protective and regulative role. In the absence of fascia 
separating epicardial adipose tissue and myocardium, potential interactions between these 
tissues can take place. Acting as a buffer, epicardial fat accumulates and releases free 
fatty acids (FFAs) when needed in order to prevent lipotoxicity or to provide myocardium 
with energy (Gaborit et al., 2013; Talman et al., 2014; Guzzardi and Iozzo, 2011). As an 
endocrine organ, epicardial adipose tissue produces pro- and anti-inflammatory 
adipocytokines (Baker et al., 2006). In comparison to subcutaneous adipose tissue, it 
expresses considerably higher amount of monocyte chemoattractant protein-1 (MCP-1), 
IL-1β, IL-6, soluble IL-6 receptor and TNF-α (Guzzardi and Iozzo, 2011). Much 
uncertainty still exists about the physiological impact of pericardial fat (Mazurek et al., 
2003). 
 
There is no general agreement about the normal thicknesses and volumes of epicardial 
and pericardial fat. It is established from the variety of studies that cardiac fat depots 
correlate with gender, age and ethnicity. Thus, men tend to have larger amount of cardiac 
fat than women. It increases with ageing. Moreover, cardiac fat volumes seem to be  larger 
in people of Caucasian race (Iozzo et al., 2009; Alexopoulos et al., 2010).  
 
The different methods used for the assessment of intrathoracic adipose tissue volume also 
explain part of the variability between studies. Noninvasive imaging is typically done 
with ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI). 
Echocardiographic measurement of epicardial adipose tissue thickness was proposed as 
a reliable and simple method in clinical practice with no extra cost since patients with 
high CV risk are regularly referred to echocardiography (Iacobellis et al., 2003). 
However, it is not always possible to distinguish with echocardiography epicardial fat 
from pericardial fat due to poor visualization of pericardium. Usually, echocardiography 
gives higher epicardial fat volumes, whereas the amount of pericardial fat might be 
underestimated (Bertaso et al., 2013). 
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Computed tomography (CT) is considered as an accurate imaging technique for 
measurement of cardiac fat (Dey et al., 2010). Its high spatial and temporal resolution 
provides precise quantification of epicardial and pericardial adipose tissue volumes 
separately (Marwan and Achenbach, 2013). However, this method has a number of 
limitations such as the radiation exposure and relatively high cost. 
 
Magnetic resonance imaging (MRI) does not use ionizing radiation, but it suffers from 
other serious drawbacks. High price and time-consuming manual image analysis of 
adipose tissue are some of the problems (Dey et al., 2012). With use of whole body MRI, 
it is also technically challenging to accurately differentiate between visceral and parietal 
pericardium which can lead to incorrect measurement of epicardial and pericardial fat 
depots, whereas cardiac MRI can make this distinction (Kessels et al., 2006). 
 
Although some research has been carried out on the in vivo quantification of intrathoracic 
adipose tissue, still there is no “gold standard” method (Rosito et al., 2008). Role of CT 
and MRI is increasing due to the possibility of volumetric measurement. Table 1 shows 








Amount of intrathoracic fat (mean) 
CT 





PAT and intrathoracic fat 101 and 178 
g in women and 126 and 262 g in men, 
respectively 
(Mahabadi et al., 
2009) 
1267 
PAT 114 ± 46 g, intrathoracic fat 106 
± 58 g 
(Iwasaki et al., 
2011) 
197 EAT 91± 37 g (range 10,6 to 242,6 g) 
(Alexopoulos et al., 
2010) 
214 EAT 73 ± 39 g (range 9 to 230 g) 
(Wang et al., 2010) 224 EAT 102 ± 40 g 
MRI 
(Flüchter et al., 
2007) 
28 (healthy) 
EAT 64,6 ± 21.2 g (range 28.2 to 
112.8 g) 
(Gaborit et al., 
2012) 
30 (healthy) EAT 51 ± 24 g ( range 17 to 116 g) 
(Wong et al., 2011) 20 (healthy) PAT 155 g (range 120 to 174 g) 







2.2 Metabolic syndrome and type 2 diabetes mellitus 
 
2.2.1 Clinical criteria for diagnosis of metabolic syndrome 
 
Metabolic syndrome is a group of risk factors leading to CVDs and diabetes. It was 
described by Reaven in 1988 as a cluster of several risk factors, such as hyperglycemia, 
hypertension, dyslipidemia, which cause heart disease. He used the term Syndrome X, 
which was later renamed as metabolic syndrome (Reaven, 1988). 
 





At the moment, there are several clinical criteria recommended by different organizations. 
During National Cholesterol Education Program Expert Panel in 2002, Adult Treatment 
Panel III (ATP III) proposed 5 parameters associated with metabolic syndrome. Three of 
five risk factors should be presented in order to make a diagnosis of metabolic syndrome. 
Abdominal obesity is considered as the predominant cause of metabolic syndrome 
(National Cholesterol Education Program, 2002). In 2006, International Diabetes 
Federation (IDF) updated these values. Table 2 shows an overview of updated clinical 
criteria provided by IDF. According to the new worldwide definition of metabolic 











for women with some variations between different ethnic groups. Thus, in the USA 
guidelines ATP III values are still in use; for Asian ethnicities defining levels are smaller 







> 94 cm 
(ATP III > 102 cm) 
> 80 cm 
(ATP III > 88 cm) 
Raised triglycerides 
≥ 150 mg/dL, 
or specific treatment 
Reduced HDL cholesterol < 40 mg/dL < 50 mg/dL 
Elevated blood pressure ≥ 130/ ≥ 85 mm Hg 
Increased fasting glucose 
≥ 100 mg/dL 




IDF has proposed a number of additional parameters associated with metabolic 
syndrome, such as abnormal body fat distribution, dysglycemia, proinflammatory and 
prothrombotic state, etc. Further research in this field could also be conducted to 
determine the impact of these risk factors for diagnosis (International Diabetes 
Federation, 2006). 
 
According to World Health Organization (WHO) clinical criteria, insulin resistance is a 
mandatory risk factor for diagnosis of metabolic syndrome. Apart from insulin resistance, 
two other risk factors should be presented (Alberti and Zimmet, 1998). 
	
American Association of Clinical Endocrinologists (AACE) clinical criteria combine 
criteria of ATP III and WHO definition of metabolic syndrome. Although, there is no 
required number of risk factors, a physician diagnoses insulin resistance in accordance 
with clinical perception. When a patient’s condition transforms to T2DM, the term insulin 
resistance is not relevant anymore (Einhorn et al., 2003). 
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Cardiovascular diseases are the major clinical outcomes of metabolic syndrome.  Insulin 
resistance is the second most common clinical outcome. Majority of people with 
metabolic syndrome have increased risk for T2DM (Reaven, 1988). Apart from 
cardiovascular diseases and type 2 diabetes mellitus, patients with this syndrome suffer 
from other conditions, such as fatty liver, asthma, polycystic ovary syndrome (Grundy et 
al., 2004). 
 
2.2.2 Visceral adipose tissue 
 
Energy is stored into subcutaneous adipose tissue and visceral adipose tissue. In adults, 
subcutaneous fat constitutes the largest part of the total body fat. Visceral adipose tissue 
refers to the fat surrounding internal organs. To date, research has shown that visceral fat 
is metabolically more active than subcutaneous fat and is significantly correlated with 
cardiovascular risk factors and the metabolic syndrome (Wajchenburg, 2014). In 
abdomen, visceral adipose tissue can be approximately partitioned into intraperitoneal 
and extraperitoneal compartments by delineation along ascending and descending colons 
and kidneys. The reason for this separation is that blood from intraperitoneal 
compartment drains into the portal vain while blood from retroperitoneal compartment 
drains into inferior vena cava (Abate et al., 1994). Likely, metabolism of these two 
compartments differ, which is an important issue for future studies. 
 
There are several methods of measuring visceral fat: anthropometric measurements and 
imaging techniques. Waist circumference is the simplest but less precise way of visceral 
fat estimation. This anthropometric technique is also considered more reliable in 
quantification of subcutaneous fat rather than visceral abdominal fat (Bonora et al., 1995). 
Imaging techniques, such as MRI or CT, provide precise measurements; however, these 
methods have several disadvantages. MRI cannot provide adequate calculation of visceral 
fat in patient with obesity. A potential problem of CT scans is the exposure to ionizing 
radiation. Moreover, both MRI and CT are expensive techniques. Recent evidence 
suggests abdominal ultrasonography as a reliable imaging technique for visceral adipose 
tissue assessment due to its low price, accuracy and easy application (Ribeiro-Filho et al., 
2000; Iacobellis et al., 2003). 
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There is strong evidence that amount of visceral fat increases with age, both in men and 
women (Enzi et al., 1986). It was also shown that, since visceral fat is metabolically more 
active, weight loss affects visceral fat more than subcutaneous fat due to higher level of 
lipolysis (Bjorntorp, 1992). 
 
As it was previously mentioned, visceral adipose tissue has the highest lipolytic activity 
which leads to the increased free fatty acids (FFA) flux to the liver. The flux tends to 
intensify gluconeogenesis and production of very low-density lipoproteins (VLDL) 
which results in ectopic triglyceride accumulation. Above all, the flux leads to reduced 
hepatic insulin extraction, which in return increase level of insulin; finally, insulin inhibits 
hepatic glucose production (HGP) (Wajchenburg, 2014). Apart from preferential 
oxidation of FFA over glucose, various mechanisms explaining insulin resistance has 
been suggested (Delarue and Magnan, 2007). These are oxidative stress, inflammation, 
lipid metabolites in skeletal muscle and liver which alter insulin signaling pathway by 
activating serine kinase cascade (Petersen and Shulman, 2006; Boden, 2011). Thus, 
excessive levels of FFA will certainly lead to failure of ß-cells and the development of 
T2DM (Wajchenburg, 2014). As shown in Figure 4, this process demonstrates a distinct 
relationship between the amount of visceral fat and insulin resistance through the 












2.2.3 Type 2 diabetes mellitus 
 
Type 2 diabetes mellitus has been known as non–insulin-dependent diabetes and makes 
up about 90% of all diabetes cases. It occurs due to a relative insulin deficiency on the 
background of insulin resistance. This key feature contrasts with type 1 diabetes mellitus 
when absolute insulin deficiency leads to ketoacidosis and death in case insulin is not 
replaced. Due to quite slow development of hyperglycemia the signs of T2DM can 
initially go unnoticed for years, which leads to increased risk of diabetes complications 
in undiagnosed patients (Walker, 2013). 
 
Over the past few decades, the incidence of diabetes has been steadily increasing in 
countries of all income levels, especially in low- and middle-income countries. T2DM is 
a major cause of cardiovascular morbidity and mortality. It is associated both with 
microvascular complications, including nephropathy, retinopathy and neuropathy, as well 
as with macrovascular complications such as CV diseases, cerebrovascular disease and 
peripheral artery disease. Overweight or obese, being related to T2DM, is a further risk 
factor for hypertension which is a common co-morbidity in both CV diseases and T2DM 
(American Diabetes Association, 2016). 
 
Glucose homeostasis is normally maintained by several coordinated actions: 
gluconeogenesis inhibition, glycolysis activation and stimulation of glucose uptake into 
peripheral insulin-dependent tissues (skeletal muscles and adipose tissue) (DeFronzo and 
Tripathy, 2009). Insulin, being released from b-endocrine cells of Islets of Langerhans in 
pancreas, is the main regulator not only glucose metabolism but also lipid metabolism. It 
increases triglyceride synthesis, FFAs synthesis, decreases lipolysis, ketogenesis and 
fatty acid oxidation. FFA oxidation provides energy for further gluconeogenesis and leads 
to ketone bodies production. 
 
Insulin resistance, a key feature in T2DM, is progressively increasing over time. In the 
early, asymptomatic stage, insulin resistance is well compensated by increased release of 
insulin from pancreatic cells (hyperinsulinemia). Development of β-cell defect leads to 
impaired glucose tolerance (IGT). In the clinical stage, with a greater loss of b-cell 
function, hyperglycemia becomes manifest, hepatic glucose production increases along 




The mechanism of insulin resistance in T2DM remains unclear. Apart from genetic factor, 
the most common theory is based on T2DM association with overweight or obesity. In 
obese, bigger amount of metabolically active visceral adipose tissue produces more FFAs 
due to increased rate of lipolysis. Circulated FFAs can become a fuel supply for oxidation 
in peripheral tissue replacing glucose, thus affecting insulin resistance. In addition, excess 
visceral adiposity leads to greater release of adipokines, regulatory hormones which may 
have an influence on insulin sensitivity. Finally, adipose tissue tends to accumulate a 
considerable amount of macrophages causing chronic inflammation. Increased 
inflammation is thought to be another reason of insulin sensitivity in obese individuals 
(Guilherme et al., 2008). 
 
2.2.4 Therapeutic interventions 
 
Standards of medical care in T2DM include pharmacological therapy (oral agents, non-
insulin injectables, insulin replacement), medical nutrition therapy, exercise therapy 
(physical activity promotes glucose uptake in skeletal muscles), weight management 
(weight loss improves insulin sensitivity) and bariatric surgery (in terms of weight loss) 
(American Diabetes Association, 2016). 
 
1. Pharmacological therapy 
 
Glycemic control is the main goal of diabetes management. Chronic hyperglycemia 
causes glycation of proteins as well as other changes in chemicals. Glycosylated 
hemoglobin (HbA1c) is the most accurate and objective method to measure glycemic 
control since hemoglobin can be easily obtained from a blood sample (Walker, 2013) A 
wide range of pharmacotherapy is available, the most common oral antihyperglycemic 
drugs are biguanides (metformin), sulphonylureas, thiazolidinediones, GLP-1 analogs, α-
glucosidase inhibitors etc. 
 
Insulin resistance can be another prospective target of drug intervention (Alberti and 
Zimmet, 1998). At the moment, there are two classes of approved drugs on the market – 
metformin and thiazolidinedione pioglitazone, which reduce insulin resistance. Further 
investigation in the field of drug discovery is going on (Bailey, 2005). 
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The majority of recently available diabetes drugs have several limitations such as cost, 
dosing adjustments and schedules, adverse effects, etc.; thus, alternative therapies have 
been developed. Recently, researchers have shown an increased interest in sodium 
glucose cotransporter 2 inhibitors (SGLT 2), novel oral antihyperglycemic drugs, which 
decrease glucose reabsorption in the kidney, thus increasing urinary glucose excretion. 
They improve glycemic control with a low risk of hypoglycemia. Due to their original 
insulin-independent mode of action specifically targeting the kidney, they can be used in 
patients with insufficient insulin release (Vasilakou et al., 2013). Beyond glycemic 
control, these drugs have other beneficial effects on CV risk factors. These factors include 
decrease in blood pressure, weight, visceral adiposity, hyperinsulinemia, arterial stiffness, 
albuminuria, circulating uric acid levels and oxidative stress (Inzucchi et al., 2015). At 
the moment, there are 4 drugs approved by US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA): canagliflozin, dapagliflozin, empagliflozin and 
ertugliflozin (Inzucchi et al., 2015; MSD, 2017). Another antidiabetic drug, liraglutide 
(an analog of GLP-1) has also shown significant cardioprotective effects, including 
weight loss (Nauck et al., 2009; Marso et al., 2013). Recently, it has been found that 
liraglutide reduced epicardial adipose tissue volume which can be associated with its 
cardioprotective effects (Iacobellis et al., 2017). 
 
As for metabolic syndrome, drug therapy is particularly important as a secondary 
management strategy. However, very little is known about pathophysiological 
mechanisms of metabolic syndrome, and no specific treatment has been discovered. 
Various drugs can be used to target individual metabolic risk factors. For example, 
atherogenic dyslipidemia can be treated with use of statins or fibrates, high BP – with use 
of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and other 





According to IDF and ATP III, obesity is the predominant cause of metabolic syndrome 
and, therefore. it is suggested that overweight should be the main target of therapy. 
Recommendations focus on weight reduction together with increased physical activity. 
Weight reduction can be achieved by calorie limitation and change in dietary habits. Such 
clinical management has an influence on different risk factors – weight loss contributes 
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to serum cholesterol, triglycerides, glucose and BP reduction, reduces insulin resistance, 
and it increases HDL cholesterol (National Cholesterol Education Program, 2002; 
International Diabetes Federation, 2006). 
 
3. Exercise therapy 
 
Different kinds of exercise, such as aerobic exercise, resistance exercise, endurance and 
passive exercise has been shown to have a great impact on T2DM and metabolic 
syndrome. Although the mechanism of the impact of exercise therapy on T2DM is 
unclear, it is known that physical activity promotes glucose uptake in skeletal muscles 
via glucose transporter 4. During the exercise it leads to reducing plasma glucose level in 
diabetic patients (Thent et al., 2013). 
 
	
It has conclusively been shown that large amount of cardiac fat correlates with 
cardiovascular risk factors. Data from several sources have identified the decreased 
epicardial adipose tissue volume and thickness associated with weight loss, either through 
low-calorie diet or bariatric surgery (Willens et al., 2007; Iacobellis et al., 2008b). 
Collectively, these studies outline a critical role for the management of cardiac adipose 
tissue. Further research should be undertaken to investigate the possible ways of 
controlling the size of cardiac fat. 
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2.3 Role of epicardial and pericardial fat in T2DM 
 
Most studies show the associations between cardiac adipose tissue depots (epicardial, 
pericardial fat and MTC) and metabolic syndrome (Iacobellis and Willens, 2009; 
Calabuig et al., 2017). Increased low-density lipoprotein (LDL) cholesterol and arterial 
blood pressure, decreased adiponectin and fasting insulin, as well as other components of 
metabolic syndrome have shown a correlation with excessive amount of epicardial 
adipose tissue (Iacobellis et al., 2003). According to some studies, pericardial fat depots 
is also correlated with metabolic components (Sironi et al., 2012; Rosito et al., 2008; 
Iacobellis et al., 2005; Sacks and Fain, 2007). In addition, it has been found that epicardial 
adipose tissue is related to unstable angina, myocardial infarction and coronary plague 
vulnerability (Homsi et al., 2016; Zhou et al., 2016; Ito et al., 2012). 
 
There are few theories which can explain high risk of CV diseases. One of them is a 
mechanical theory. Large amount of pericardial adipose tissue can affect cardiac structure 
and function – ventricles should pump blood with more effort due to mechanical restraint. 
 
Since epicardial adipose tissue has the same source of microcirculation as myocardium 
and due to its close proximity to the heart, it has been suggested that tissue inflammation 
and vasocrine effects can play a role in high risk of CV diseases when fat depots are 
increased (Mazurek et al., 2003). Epicardial adipose tissue, similar to other visceral 
depots, produces inflammatory cytokines, chemokines and hormones. This can lead to 
amplification of existing inflammation in coronary vessels. There are two possible 
mechanisms of this influence – paracrine signaling and vasocrine signaling (Sacks and 
Fain, 2007). Previous research has indicated that high release of epicardial adipokines 
could lead to a coronary atherogenesis (Lee et al., 2009). However, some consequences 
of adipocyte-derived inflammation might be favourable. Thus, inflammatory mediators 
released from epicardial adipose tissue can cause collateral vascularization in patients 
with obstructive coronary artery disease by stimulation of angiogenesis (Mazurek et al., 
2003). 
 
However, the evidence for this relationship is inconclusive as some authors tend to 
explain it by strong correlation between epicardial and visceral abdominal adipose tissue 
(Iacobellis et al., 2003). Moreover, in light of recent research, it has conclusively been 
shown that the amount of epicardial fat does not necessarily correlate with overall obesity. 
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In a small study conducted by Iacobellis et al. (2003), two men underwent physical 
examination and MRI for the assessment of body fat disposal. Whereas they were of the 
same age and had the same BMI, MRI revealed a representative difference. The first 
patient showed a severe visceral obesity along with significant epicardial adipose tissue 
thickness. Examination of the second patient found a large amount of subcutaneous fat 
along with normal epicardial fat thickness values. This study provided important 
suggestion about epicardial adipose tissue as a sign of visceral obesity independent of 
BMI. 
 
Cardiac adipose tissue plays a crucial role in the development of diabetes mellitus 
(Iacobellis and Malavazos, 2010). Increased epicardial fat depots produce excessive 
amount of inflammatory mediators, FFAs, adiponectin, which results in impaired glucose 
metabolism and diabetes mellitus (Noyes et al., 2014). Previous research conducted in 
non-diabetic patients has shown that increased cardiac adiposity, particularly increased 
epicardial fat depots, is related to impaired fasting glucose (Iacobellis et al., 2008a). 
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2.4 Magnetic resonance imaging 
 
Since the development of nuclear magnetic resonance (NMR) in 1946 by Bloch and 
Purcell, the possible use of the finding has been attracting a lot of interest (Bloch et al., 
1946; Purcell et al., 1946). In 1970s, the idea of MRI as a new imaging technique captured 
the interest of researchers (Lauterbur, 1973). Today, MRI is a commonly used imaging 
modality which allows to assess both morphology and physiological processes of the 
body. The great advantage of MRI over other imaging modalities such as CT or positron 
emission tomography (PET) is that it does not use ionizing radiation. However, there are 
some limitations. MRI cannot be performed in patients with metal implants and heart 
pacemakers due to potential risks. Applications of the technique vary from visualization 
the vascular system by magnetic resonance angiography or brain function by functional 
MRI to chemical and physical assessment of individual molecules with use of magnetic 
resonance spectroscopy. 
 
The main idea behind MRI is the imaging of a proton located in the nucleus of a hydrogen 
atom. A proton has two main properties – a spin and a positive charge. An electrical 
charge in motion is called an electrical current, which in addition is followed by a 
magnetic field (Westbrook et al., 2011). When a proton is placed in an external magnetic 
field, the spin rotates in two directions – with or against the direction of the magnetic field 
(Fig. 5). 
 
An MRI mainly comprises of a super conducting magnet made of super conducting wire, 
gradient coils and RF coils. In order to generate magnetic field, current is introduced in 
the super conducting wire. The gradient coils are required for spatial encoding of 
magnetic signal while the RF coils are necessary for detections of electron spin from 
within the body as well as for producing the B1 magnetic field. This magnetic field helps 
in rotating the spins. The spin of the electrons detected by the RF coils is the MRI signal 
which is digitized using a control circuit digitizer and is transferred to a computer where 
an inverse Fourier transform is used to convert the digitized signal into image (McRobbie 
et al., 2006). 
 
As said before, MRI signals are mainly generated by the quantum property termed ‘spin’ 
of a hydrogen proton which is abundant in humans as they are typically comprised of 
70% of water. The spin of this hydrogen nucleus gives a transition dipole moment which, 
	 19	
in a strong magnetic field like that of an MRI resides in two energy levels. They can either 
be parallel or anti-parallel to the magnetic field, the later having a slightly higher energy. 
Majority of these ‘spins’ reside in the lower energy state. The difference between the 
higher and lower energy state is determines the strength of the MR signal. The difference 
and hence the strength of the signal can be enhanced by using a stronger external magnet. 
This magnet also makes the hydrogen protons undergo a phenomenon called precession. 
Precession refers to the ‘wobble’ that the top of the spinning proton undergoes because 
of gravity. This precession frequency of the spinning proton is also known as Larmor 
frequency. This is also dependent on the strength of the magnetic field (Hashemi et al., 































After a patient is placed in the scanner, the protons align parallel or antiparallel to the 
magnetic field. The magnetic field emits radio frequency (RF) pulse which leads to 
energy exchange with the protons. It is important that the RF pulse and the protons have 
the same frequency – a phenomenon called “resonance”. As a result, some protons 
exchange their energy, a new transversal magnetization appears, thus the longitudinal 
magnetization is decreased (Schilds, 1991). When the RF pulse is stopped, the protons 

































Longitudinal relaxation, or spin-lattice relaxation, (T1) is a time constant describing the 
process of longitudinal magnetization recovery. In a similar way, transverse relaxation, 








magnetization reduction (Kullberg, 2007). T1 relaxation time is normally longer than T2 
relaxation time – in absolute values T1 is about 300-2000 ms, and T2 is about 30-150 ms 
(Schilds, 1991). The resulting curves are shown in figures 6 and 7. 
 
The RF excitation and MRI signal detection by the scanner is repeated multiple times, 
resulting in image composition. T1 and T2 relaxation time vary with the magnetic field 
strength and in different tissues. Thus, T1 is longer in liquids and shorter in fat tissue. 
T2 is longer in water than in other liquids containing macromolecules (Schilds, 1991). 
 
Perfect soft tissue contrast is one of the many reasons why MRI technique is so 
commonly used in practice. Together with good spatial resolution and lack of ionizing 




3 AIMS AND HYPOTHESES 
 
The objective of the study is: 
  
- To evaluate the association between intrathoracic adipose tissue mass and 
metabolic components in patients with type 2 diabetes mellitus 
 





4 MATERIALS AND METHODS 
 
4.1 Study population and design 
 
I analyzed cross-sectional T2DM patients who had previously participated in a clinical 
trial  (clinicaltrials.gov identifier: NCT02426541)  A group of 31 female and male type 2 
diabetes mellitus patients aged 35-70 years old with HbA1c ³ 6.5% and £10.5% 
participated in this study. Females were of non-childbearing potential. The study was 
performed in accordance with ethical principles that have their origin in the Declaration 
of Helsinki and are consistent with guidelines of the International Conference on 
Harmonization, Good Clinical Practice and applicable regulatory requirements. 
Participants were fully informed of the possible risks and benefits associated with this 
study, and their consent was obtained prior to performing any study-related activity. 
 




1) Signed informed consent 
2) Female or male patients aged 35-70 years old 
3) Type 2 diabetes mellitus defined as HbA1c of ³ 6.5% and £10.5% 
4) Stable T2DM treatment (more than 3 months) 
5) BMI £ 40 kg/m2 





1) Involvement in the study planning or assessment 
2) Previous participation in this study or another clinical study during the last 
3 months 
3) Metal implants, a pacemaker or other contraindications to MRI 
4) Clinically significant disorder or disease which might affect the results of 
the current study 
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5) Volume depleted patients 
6) Recent cardiovascular events (within 2 months prior the study) 
7) Congestive heart failure defined as New York Heart Association (NYHA) 
class IV, unstable or acute congestive heart failure 
8) BP ³	165/100	mm	Hg 
9) Recent history of drug abuse or alcohol abuse 
10)  Weight loss more than 5% within 3 months prior to study 
 
Subjects underwent:   
• Brief physical examination and vital signs (blood pressure and pulse 
measurements) 
• Collection and measurements of body weight and waist circumference 
• MRI scan 
• Blood sampling 
• Euglycemic hyperinsulinemic clamp 
• Collection of adverse events and use of concominant medications 
 
4.2 Study assessments 
 
4.2.1 Magnetic resonance imaging 
 
Magnetic resonance imaging was performed to assess fat depots and body composition. 
The MRI scans were performed using the PET MRI scanner at Turku PET Centre, Turku, 
Finland. 
 
MRI data evaluation was performed by Carimas (version 2.9; Turku PET Centre, Turku, 
Finland). With use of the previously validated basic analysis protocol for measuring 
volume of cardiac fat, three-dimensional volumes of interest (VOIs) was manually drawn 
in the epicardial and pericardial adipose tissue compartments while avoiding bone, 
muscle and skin. Separate region of interest (ROI) segments were drawn from the highest 
edge of pericardium to its lowest edge paying attention to the anatomical structures as it 
gets close to the ends (towards the liver or towards the pulmonary artery). Within the 
volumes of interest, fat was defined as voxels within a window of different Hounsfield 
units for each case. The analysis continued with ROI drawing of all the fat around 
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pericardium (intrathoracic fat). At the top of the heart, the intrathoracic fat ROI segments 
should be drawn from the same slice as in the pericardium analysis, but at the bottom 
drawing can be continued as long as intrathoracic fat continues. The volume of pericardial 
fat was quantified by subtraction of epicardial fat from intrathoracic fat. To convert the 
measured volumes into weight, an adipose tissue density of 0,9196 g/ml was used. 
 
































4.2.2 Euglycemic-hyperinsulinemic insulin clamp 
 
Euglycemic-hyperinsulinemic clamp is the gold-standard method to assess insulin 
sensitivity in humans. The procedure was performed on fasting subjects based on the 
original protocol by Defronzo et al. The insulin level was raised to	100 muU/ml and 
maintained by a continuous insulin infusion by insulin, while the glucose concentration 
was maintained at a normal level. Under a condition of steady euglycemia (the final 40 
min of study), the amount of infused glucose equals the amount of the whole body glucose 
uptake (M-value) (DeFronzo et al., 1979).  
 
4.2.3 Other measurements 
 
The laboratory parameters (HbA1c, fasting plasma glucose, insulin, glucagon, GLP-1) 
were measured to assess glycemic efficacy. During eugycemic insulin clamp blood 
samples were taken to analyze FFAs, insulin and glucose. The local hospital laboratory 
at Turku PET Centre, Turku, Finland was used for the analyses. 
 
The subject’s weight was recorded in kilogram (kg), with light clothes and no shoes; the 
subject’s height was recorded in centimeters, with no shoes; body mass index (BMI) was 
calculated as weight in kilograms divided by height in meters squared. The subject’s waist 
circumference was measured in centimeters midway between the lowest rib and the iliac 
crest. 
 
Vital sign measurements included sitting systolic and diastolic blood pressure and heart 
rate. Vital signs were measured after the patient rests for approximately 5 minutes and 
with the patient in a sitting position. The blood pressure measurement was repeated after 
at least 30 seconds and the average of the two readings recorded. 
 
The OGTT was performed on fasting subjects. Liquid containing 75 g of glucose was 
given, and blood samples were taken at the zero time (baseline), and at 15, 30, 60, 90, 
120 min during the test to measure glucose and insulin levels. 
 
The Homeostatic Model Assessment (HOMA) calculator (The University of Oxford, 
2013) was used to calculate ß-cell function, insulin sensitivity and insulin resistance 
(Matthews et al., 1985). As it can be seen from the figure 9, ß-cell function and insulin 
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sensitivity are estimated as percentages of a normal reference population while insulin 






4.3 Statistical analysis 
 
Data analysis was performed using SPSS (version 23; SPSS, Chicago, IL). Continuous 
data was reported as mean ± SD of the mean, and categorical data was reported as 
percentages. For justification of analyses, the normality of data distribution was checked 
using Shapiro-Wilk test. Logarithmic transformation was used to achieve the normal 
distribution assumption when necessary. Transformed model based means were 
translated back to the original scale. Comparison of variables between two groups was 
performed with independent samples T test, or non-parametric Mann-Whitney U test. 
Comparison of variables between 3 groups was performed using Kruskal-Wallis test. 
Correlations of cardiac fat volumes and anthropometric and clinical variables were 
performed using Pearson´s correlation (or Spearman’s rank-order correlation analysis for 
non-normally distributed variables). Multiple regression analysis was performed to 
calculate the contribution of different covariates to the prediction of epicardial fat volume. 





5.1 Subjects characteristics 
 
Table 3 presents an overview of anthropometric and clinical characteristics of study 
subjects. 
 
Age, years 62 ± 8 
Male, % 77,4 % 
Anthropometric measurements and vital signs 
Height, cm 172 ± 9 
Weight, kg 95 ± 14 
Waist, cm 110 ± 10 
BMI, kg/m2 32 ± 4 
BP syst, mm Hg 149 ± 14 
BP diast, mm Hg 85 ± 8 
Heart rate, /min 69 ± 10 
Laboratory measurements 
FFA, mmol/l 0,67 ± 0,17 
FPG, mmol/l 9,1 ± 1,8 
HbA1c, mmol/mol 52 ± 6 
GHb-A1c, % 6,9 ± 0,6 
HOMA 
ß-cell function, % 61.6 ± 29.6 
Insulin sensitivity, % 46.9 ± 25.1 
Insulin resistance 2.82 ± 1.55 
Cytokines 
IL-6, pg/ml 5,14 ± 6,11 
TNF-α, pg/ml 4,23 ± 1,86 
MCP-1, pg/ml  418,82 ± 214,11 
 
Table 3. Basic characteristics of study subjects 
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5.2 Epicardial and pericardial fat depots 
	
Cardiac fat and gender 
 
Figure 10 shows the distribution of cardiac fat between males (n = 24) and females (n = 
7). From the chart it can be seen that males tend to show higher cardiac adipose tissue 
mass than females. Difference in pericardial fat and total intrathoracic fat is statistically 
significant (pericardial adipose tissue 272 and 176 g, p = .013; intrathoracic – 535 and 
410 g, p = .018). No statistically significant difference in epicardial adipose tissue 

















































Epicardial fat - age














Pericardial fat - age














Intrathoracic fat - age
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Figure 11 shows the correlation between cardiac fat depots and age. From the charts it 
can be seen that there was no evidence that age has an influence on heart adiposity. 
 
Cardiac fat and waist circumference 
 
Although the scatterplot showed weak positive correlation between epicardial adipose 
tissue mass and waist circumference (Fig. 12), statistical analysis of the data confirmed 
the significance of these findings (Table 4). Also there was the same strength positive 
correlation between total intrathoracic fat mass and waist circumference which was 










Pearson Correlation 1 .378* 
 Sig. (2-tailed)  .036 
 N 31 31 
Waist, cm Pearson Correlation .378* 1 
 Sig. (2-tailed) .036  
 N 31 31 




































Pearson Correlation 1 .373* 
 Sig. (2-tailed)  .039 
 N 31 31 
Waist, cm Pearson Correlation .373* 1 
 Sig. (2-tailed) .039  
 N 31 31 
* Correlation is significant at the 0.05 level (2-tailed). 
   
Table	5.		Statistical	orrelation	between	epicardial	fat	depot	and	waist	circumference 
 
Cardiac fat and body fat distribution 
	
Table 6 shows the comparison of epicardial and pericardial fat mass depending on 
different conditions of body fat distribution. Predominant visceral fat accumulation is 
represented by waist circumference > 102 cm in men and > 88 cm in women. Predominant 
peripheral fat accumulation is represented by waist circumference < 102 cm in men and 
< 88 cm in women. 
 
Subjects with predominant visceral fat accumulation showed higher cardiac adipose 
tissue mass than subjects with predominant peripheral fat distribution, however, there 






















Intrathoracic fat - waist
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among subjects with predominant visceral fat accumulation and subjects with peripheral 
fat. No significant differences in age occurred. 
	
	
 All (n = 31) 
Visceral fat 
accumulation 
(n = 24) 
Peripheral fat 
accumulation 
(n = 7) 
p 
Age, years 62 ± 8 62 ± 8 63 ± 9 NS 
BMI, kg/m2 32 ± 4 33.6 ± 3.4 26.0 ± 1.5 < .001 
Epicardial fat 
mass, g 257 ± 54 261 ± 61 240 ± 22 NS 
Pericardial fat 
mass, g 250 ± 98 251 ± 105 243 ± 80 NS 
Intrathoracic 







Cardiac fat and degree of obesity 
 
The bar chart below illustrates the association between cardiac adipose tissue mass and 
degree of obesity. The subjects were divided into 3 groups according to their BMI values: 
lean (BMI < 24.9), overweight (BMI between 25.0 and 29.9) and obese (BMI > 30.0). 
Further statistical test revealed that no significant correlation between these groups was 





























Cardiac fat and arterial blood pressure 
 
It can be seen from the data in Table 7 that no evidence was found for associations 
between cardiac fat depots and arterial blood pressure. 
 




Epicardial fat mass Correlation Coefficient -.253 -.079 
 Sig. (2-tailed) .169 .672 
 N 31 31 
Pericardial fat mass Correlation Coefficient .077 -.027 
 Sig. (2-tailed) .680 .885 
 N 31 31 
Intrathoracic fat mass Correlation Coefficient -.001 -.012 
 Sig. (2-tailed) .997 .948 
 N 31 31 
	
Table	7.	Correlations	between	cardiac	fat	depots	and	arterial	blood	pressure.	
*	Correlation	is	significant	at	the	0.05	level	(2-tailed).	 	 	 	 	
**	Correlation	is	significant	at	the	0.01	level	(2-tailed).	 	 	 	 	
 
Cardiac fat and smoking 
 
As shown in Fig. 15, smoking subjects reported a larger mass of all cardiac fat depots. 
However, no statistical evidence was found for non-linear associations between smoking 
and non-smoking subjects (epicardial fat 250 and 289 g, p = .629; pericardial fat 240 and 







Cardiac fat and alcohol consumption 
 
The analysis of relationship between cardiac fat and alcohol consumption showed that 




























A Spearman's rank-order correlation was run to assess the relationship between the 
cardiac fat measurements and a range of anthropometric and clinical characteristics of 
study subjects (Table 8). 
 
There was no significant correlation regarding weight, BMI, BP and heart rate, diabetes 
duration, different laboratory measurements, measurements from the clamp and the 
results obtained from HOMA. There was a positive correlation between epicardial fat 
mass and waist circumference, which was statistically significant, rs = .398, p = .027. 
Also, there was a strong positive correlation between epicardial and total thoracic fat 
mass, which was statistically significant, rs = .663, p < .001, as well as between epicardial 




















Don't drink (n = 11) Drink (n = 20) 
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mass, rs = .950 p < .001. In addition, a positive correlation was present between thoracic 











 Epicardial fat 
mass 
Correlation 
Coefficient 1.000 .444* .663** .398* 
Sig. (2-tailed) . .012 .000 .027 





.444* 1.000 .950** .306 
Sig. (2-tailed) .012 . .000 .095 
N 31 31 31 31 




.663** .950** 1.000 .378* 
Sig. (2-tailed) .000 .000 . .036 
N 31 31 31 31 
Waist, cm Correlation 
Coefficient 
.398* .306 .378* 1.000 
Sig. (2-tailed) .027 .095 .036 . 










The present cross-sectional study was designed to study the association between cardiac 
adipose tissue distribution and metabolic profile of 31 patients with type 2 diabetes 
mellitus. 
 
The investigation has demonstrated that epicardial and pericardial adipose tissue masses 
are different between genders.  Men tend to have larger amount of cardiac fat than women. 
These findings complement those of earlier studies. (Iozzo et al., 2009; Alexopoulos et 
al., 2010). However, we did not found the increase in cardiac fat with aging as shown 
before. 
 
Many studies have shown the association between cardiac adiposity and metabolic 
syndrome components (Sironi et al., 2012; Rosito et al., 2008; Iacobellis et al., 2005; 
Sacks and Fain, 2007). Abdominal obesity is considered as the predominant cause of 
metabolic syndrome (National Cholesterol Education Program, 2002). Although, in the 
present study there was a significant difference in BMI among subjects with predominant 
visceral fat accumulation and subjects with peripheral fat, the study conducted by 
Iacobellis (2003) provided important suggestion about epicardial adipose tissue as a sign 
of visceral obesity independent of BMI. The present study showed that subjects with 
predominant visceral fat accumulation (waist circumference > 102 cm in men and > 88 
cm in women) showed higher cardiac adipose tissue mass than subjects with predominant 
peripheral fat distribution (waist circumference < 102 cm in men and < 88 cm in women), 
however there were no statistically significant differences. There was a definite positive 
correlation between epicardial adipose tissue mass and waist circumference, as well as 
between intrathoracic fat mass and waist circumference. The association between cardiac 
adipose tissue mass and degree of obesity according to BMI showed no difference 
between subject groups. 
 
Hypertension, being a component of metabolic syndrome, has shown a correlation with 
excessive amount of epicardial adipose tissue (Iacobellis et al., 2003). This study did not 
find significant associations between cardiac fat depots and arterial blood pressure. A 
possible explanation can be that most of the subjects were using antihypertensive 
medications which led to inconclusive results.   
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In addition, such cardiovascular risk factors as smoking and alcohol consumption, were 
tested as possible predictors of heart adiposity. The analysis of relationship between 
cardiac fat depot mass and smoking, as well as between cardiac fat and alcohol 
consumption showed no significant difference. 
 
There were few limitations in the study. As it is well known, metabolic syndrome is a 
group of risk factors leading to CVDs and diabetes (Reaven, 1988). The study group was 
consisted of patients with pre-existing type 2 diabetes mellitus admitted for the treatment. 
Thus, it was impossible to see the real picture of metabolic syndrome. Also, the number 
of participants was not adequate enough to see the associations with metabolic 
components. These results therefore need to be interpreted with caution. Secondly, the 
image quality was not optimal due to poor quality of MRI scans. Whole body MRI scans 
did not aim to assess cardiac depots. During the image analysis, I had to put together 2 
slices in order to get a complete heart image. This could lead to inadequate quantification 
of VOI voxels. Moreover, since ROIs were drawn by hand there was a significant risk of 
manual errors in quantification. Finally, there was lack of visceral fat data and lipid 
profile. Research has shown that visceral fat is metabolically more active than 
subcutaneous fat and is significantly correlated with cardiovascular risk factors and the 
metabolic syndrome (Wajchenburg, 2014). As it was previously mentioned, visceral 
adipose tissue has the highest lipolytic activity which leads to the increased free fatty acid 
flux to the liver. Excessive levels of FFA lead to failure of ß-cells and the development 
of T2DM (Wajchenburg, 2014). Thus, there is a distinct relationship between the amount 
of visceral fat and insulin resistance. Due to absent information about lipid profile of the 
subjects, this study was unable to investigate the association between such metabolic 
components as triglycerides and HDL cholesterol levels and cardiac fat depot volumes. 
 
In conclusion, study results showed that cardiac fat mass measurement by MRI can 
provide important information about the metabolic and cardiovascular risk, especially in 
those people who have normal BMI and/or waist circumference values. However, these 
findings do not suggest that epicardial and pericardial adipose tissue can be used as an 
indicator for metabolic syndrome. It would be interesting to investigate the association 
between cardiac fat depots and the amount of visceral adipose tissue along with lipid 
profile. Future research should therefore concentrate on the investigation of prognostic 
significance of cardiac adipose tissue and shed light on intrinsic pathophysiological 
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